What Beacon Biosignals does
Beacon Biosignals builds AI models that analyze electroencephalogram (EEG) data to identify biomarkers of brain disorders. Pharmaceutical companies and clinical researchers use its precision-medicine platform to run EEG-based clinical trials, and the company also sells an FDA-cleared at-home sleep diagnostic device called Waveband to sleep physicians and neurologists. Beacon says it is building what it calls the world's largest neurodiagnostic dataset. The company was founded in 2019 by Jacob Donoghue, Jarrett Revels, Brandon Westover and Sydney Cash.
Beacon Biosignals is a healthcare tool on Falcoscan. AI that reads EEG data to find brain-health biomarkers and speed drug trials. Falcoscan rates Beacon Biosignals with an Opportunity score of 86/100, a Saturation score of 11/100, and a Wrapper-risk score of 9/100. Market signal: rising. Beacon Biosignals is founded in 2019, currently at Series_b stage. Pricing: Paid.